Qualisure Diagnostics is pleased to announce the launch of our first diagnostic test, Thyroid GuidePx® for papillary thyroid cancer, the most common type of thyroid cancer.

Thyroid GuidePx® is the first genomic classifier available for papillary thyroid cancer. This test identifies newly discovered molecular subtypes of thyroid cancer which distinguish aggressive from more slowly growing tumors. This information gives clinicians information to better tailor treatments appropriate for their patients.

With the rapidly growing incidence of thyroid cancer, Thyroid GuidePx® is expected to become an important tool for doctors and patients to make decisions on the most appropriate course of care. Qualisure Diagnostics’ CEO, Oliver Bathe said, “We believe that this test, and others that we have in development, will make Precision Oncology the standard of care for cancer patients in the very near future.”

The test is now available from Qualisure Diagnostics, and supported by our lab partner, Protean BioDiagnostics. “We are excited to partner with Qualisure Diagnostics to expand our mission to help patients with thyroid cancer obtain access to the diagnostic services they need to better guide their treatment choices,” said Anthony Magliocco, MD, CEO of Protean BioDiagnostics.

Qualisure Diagnostics is a Calgary, Canada based developer of Precision Oncology tests for personalizing cancer care. Protean BioDiagnostics is a clinical laboratory in Orlando, FL that specializes in Precision Oncology lab tests.

For further information, contact Oliver Bathe, MD, CEO of Qualisure Diagnostics, obathe@qualisuredx.com, or visit https://www.qualisuredx.com.